MEDICAMEN BIOTECH LIMITED
BSE group Ttrade-to-trade — every trade takes delivery, no intraday netting. The exchange decides the group; it is shown because it changes how the share can be traded, not as a judgement of the company.
No fund holds it No fund disclosed this company in the latest holdings month (Aug 2026) or the two before it. Funds have owned it: the price history is below, and the flow lists show who left.
Who holds it
every fund's latest position, when it first appeared, and the price then against now · 0 rows: 0 holders and recent exits
| Fund | Weight | Since | Entry close | Now vs entry | 3-mo change | Action |
|---|---|---|---|---|---|---|
| No fund disclosed this stock in the latest month. | ||||||
A holder disclosed the stock in the latest month or the one before; an exit is listed for three disclosures. Entry close is the split- and bonus-adjusted close at the end of the month the fund first disclosed the position; “now vs entry” is price only, not the fund's return on the position. Estimated cost basis per fund from monthly unit deltas is not computed in this build.
Three-month flow
not computed
net change in Σ fund weight over the last three disclosures (percentage points summed across funds) · 0 added or entered, 0 trimmed or exited
Crowding
0 funds hold it, at an average weight of — each (0.0% summed across holders). Days-to-exit needs the aggregate MF share count and average volume; not computed for this stock.
Who moved last quarter
the three-month flow, fund by fund — largest move first
One year, adjusted
daily close, split- and bonus-adjusted
Prices are the NSE close — the company quotes on both exchanges and the NSE carries the liquidity for almost every dual listing, so one series is shown rather than two that would mostly agree. The series is adjusted for splits and bonuses so a 1:1 bonus does not read as a 50% fall. A dated corporate-action timeline (rights, demergers) is not loaded in this build and is not shown rather than guessed.